Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.
2.

Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.

Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1322-31.

PMID:
16029788
3.

Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.

Zumsteg ZS, Spratt DE, Pei X, Yamada Y, Kalikstein A, Kuk D, Zhang Z, Zelefsky MJ.

Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1012-7. doi: 10.1016/j.ijrobp.2012.07.2374. Epub 2012 Sep 14.

PMID:
22981709
4.

The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.

Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Hamstra DA.

Cancer. 2013 Feb 1;119(3):681-90. doi: 10.1002/cncr.27784. Epub 2012 Aug 14.

5.

Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer.

Tendulkar RD, Hunter GK, Reddy CA, Stephans KL, Ciezki JP, Abdel-Wahab M, Stephenson AJ, Klein EA, Mahadevan A, Kupelian PA.

Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):94-9. doi: 10.1016/j.ijrobp.2013.05.044.

PMID:
23920389
6.

Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.

Zelefsky MJ, Gomez DR, Polkinghorn WR, Pei X, Kollmeier M.

Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):529-33. doi: 10.1016/j.ijrobp.2013.02.004. Epub 2013 Mar 21.

PMID:
23523323
7.
8.

Hormone therapy and radiotherapy for intermediate risk prostate cancer.

Lee I, Sandler H.

Semin Radiat Oncol. 2008 Jan;18(1):7-14. Review.

PMID:
18082583
9.

Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer.

Krauss D, Kestin L, Ye H, Brabbins D, Ghilezan M, Gustafson G, Vicini F, Martinez A.

Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1064-71. doi: 10.1016/j.ijrobp.2010.04.004. Epub 2010 Jun 26.

PMID:
20584576
10.

The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy.

Qian Y, Feng FY, Halverson S, Blas K, Sandler HM, Hamstra DA.

Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e135-42. doi: 10.1016/j.ijrobp.2011.01.007. Epub 2011 Feb 23.

PMID:
21345617
11.

Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.

Stenmark MH, Blas K, Halverson S, Sandler HM, Feng FY, Hamstra DA.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e335-44. doi: 10.1016/j.ijrobp.2011.04.037. Epub 2011 Jun 7.

PMID:
21645976
12.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Nair B, Wilt T, MacDonald R, Rutks I.

Cochrane Database Syst Rev. 2002;(1):CD003506. Review.

PMID:
11869665
13.

High risk biochemical relapse and the timing of androgen deprivation therapy.

Ryan CJ, Small EJ.

J Urol. 2006 Dec;176(6 Pt 2):S61-5. Review.

PMID:
17084171
14.

Androgen deprivation therapy and definitive radiotherapy for prostate cancer.

Mendenhall WM, Henderson RH, Hoppe BS, Nichols RC, Mendenhall NP.

Am J Clin Oncol. 2013 Oct;36(5):530-4. doi: 10.1097/COC.0b013e31821dee4e.

PMID:
21694574
15.

Androgen deprivation use with external beam radiation for prostate cancer: results from CaPSURE.

Park S, Meng MV, Elkin EP, Speight JL, DuChane J, Carroll PR.

J Urol. 2005 Nov;174(5):1802-7.

PMID:
16217291
16.

Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.

Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML.

J Urol. 2008 May;179(5):1830-7; discussion 1837. doi: 10.1016/j.juro.2008.01.022. Epub 2008 Mar 18.

PMID:
18353378
17.

The role of androgen deprivation in the definitive management of clinically localized prostate cancer treated with radiation therapy.

Vicini FA, Kini VR, Spencer W, Diokno A, Martinez AA.

Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):707-13.

PMID:
10098424
18.

What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?

Kollmeier MA, Zelefsky MJ.

Nat Clin Pract Urol. 2008 Nov;5(11):584-5. doi: 10.1038/ncpuro1217. Epub 2008 Sep 23. Review.

PMID:
18813218
19.

The timing and extent of androgen deprivation therapy for prostate cancer: weighing the clinical evidence.

Ginzburg S, Albertsen PC.

Endocrinol Metab Clin North Am. 2011 Sep;40(3):615-23, ix. doi: 10.1016/j.ecl.2011.05.005. Epub 2011 Jul 7. Review.

PMID:
21889724
20.

Androgen deprivation and radiation therapy in prostate cancer: the evolving case for combination therapy.

Zietman AL, Shipley WU.

Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):245-6. No abstract available.

PMID:
9069292

Supplemental Content

Support Center